Year in and year out, most of the blood glucose tech you see at CES are devices that may not come out for years, if ever. That’s why it was refreshing to see Dexcom roll up to CES 2024 to talk about something a bit more tangible: its forthcoming Stelo continuous glucose monitor (CGM), a wearable sensor that provides a real-time look at your blood sugar levels.

年复一年，你在消费电子展（CES）上看到的大多数血糖技术都是多年来可能不会问世的设备。这就是为什么看到Dexcom在2024年国际消费电子展（CES）上亮相，谈论一些更具体的事情，让人耳目一新的原因：它即将推出的Stelo连续血糖监测仪（CGM），一种可穿戴传感器，可以实时观察你的血糖水平。

Unlike most CGMs, the Stelo is specifically designed to be an affordable option for Type 2 diabetics who don’t use insulin. Unlike Type 1 diabetes, where a person produces little to no insulin, Type 2 diabetes is when, over time, the body either doesn’t produce enough insulin or the body becomes insulin resistant.

与大多数CGM不同，Stelo是专门为不使用胰岛素的2型糖尿病患者设计的一种经济实惠的选择。与1型糖尿病不同，2型糖尿病是指随着时间的推移，身体产生的胰岛素不足或身体产生胰岛素抵抗。

Roughly 90 to 95 percent of all diagnosed diabetics have Type 2. However, if they control their glucose levels through oral medication rather than inject insulin, they usually don’t have access to CGM devices.RelatedContinuous glucose monitor startups still have to prove their worth Nutrisense review: a pricey way to learn a little If you’re diabetic, don’t wait for your smartwatch to replace your needles “The way CGMs work in the US is that coverage is pretty good if you take insulin, and that’s about a third of people with Type 2 diabetes,” says Dexcom COO Jake Leach.

大约90%至95%的确诊糖尿病患者患有2型糖尿病。然而，如果他们通过口服药物而不是注射胰岛素来控制血糖水平，他们通常无法使用CGM设备。相关的连续血糖监测初创公司仍然需要证明他们值得Nutrisense审查：如果你患有糖尿病，这是一种昂贵的学习方式，不要等到你的智能手表更换针头。“CGM在美国的工作方式是，如果你服用胰岛素，覆盖率相当高，约占2型糖尿病患者的三分之一，”Dexcom首席运营官杰克·利奇（JakeLeach）说。

“But there’s this large portion of about 25 million people who don’t have insurance coverage for CGMs and there really hasn’t been a product designed for them.” According to Leach, the Stelo is based on Dexcom’s existing G7 CGM platform and will last for about 15 days per sensor. However, instead of a system that centers around low blood sugar alerts — which is most useful for those who use insulin — the Stelo app is meant to provide insights around real-time readings.

“但在大约2500万人中，有很大一部分人没有CGM的保险范围，实际上还没有为他们设计的产品。”据Leach称，Stelo基于Dexcom现有的G7 CGM平台，每个传感器将持续约15天。然而，Stelo应用程序不是一个以低血糖警报为中心的系统，低血糖警报对那些使用胰岛素的人来说是最有用的，它旨在提供关于实时读数的见解。

In other words, this isn’t a device meant to save lives, but rather im.

换句话说，这不是一个旨在拯救生命的设备，而是im。